Mer­ck racks up an­oth­er win in wide-rang­ing PhI­II Keytru­da lung can­cer study, this time as so­lo ther­a­py

Mer­ck $MRK has scored an­oth­er big win in its broad range of piv­otal Keytru­da stud­ies in lung can­cer.

This morn­ing in­ves­ti­ga­tors re­port that KEYNOTE-042 demon­strat­ed that pa­tients tak­ing their PD-1 check­point drug as a monother­a­py had a sig­nif­i­cant ad­van­tage over chemo alone in front­line non-small cell lung can­cer. The study of­fers an op­por­tu­ni­ty to treat lung can­cer with­out chemo, giv­ing pa­tients a route to for­go­ing some harsh side ef­fects.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER